all report title image

MALARIA VACCINES MARKET ANALYSIS

Malaria Vaccines Market, By Vaccine Type (Pre-Erythrocytic Vaccines, Erythrocytic Vaccines, and Multi-Antigen Vaccines), By Agent (Plasmodium Falciparum, Plasmodium Vivax, and Anopheles Species), By Age (Pediatric and Adult), By Distribution Channel (Public and Private), By End Users (Hospitals, Specialty Clinics, Community Health Centers, and Homecare), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

  • Published In : Dec 2024
  • Code : CMI37
  • Pages :166
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Malaria Vaccines Market Size and Trends

The Global Malaria Vaccines Market is estimated to be valued at USD 550.1 Mn in 2024 and is expected to reach USD 1,252.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2031.

Key Takeaways of the Malaria Vaccines Market:

  • Based on vaccine type, the pre-erythrocytic vaccines segment is expected to contribute the highest share of the market with 42.1% in 2024
  • Based on agent, the Plasmodium Falciparum segment is expected to contribute the highest share of the market with 45.6% in 2024
  • Based on age, the pediatric segment is expected to contribute the highest share of the market with 52.3% in 2024
  • North America is expected to top the global market with 38.4% share, followed by Asia Pacific with 27.7% share in 2024

Market Overview:

Factors, such as rising global incidences of malaria, growing government support, and increasing R&D funding by private and public organizations, are expected to drive the demand for novel and effective malaria vaccines. Currently, there is no highly effective vaccine for malaria however few vaccines are under development which shows promise. If approved, these vaccines could help reduce malaria burden globally and complement other preventive and therapeutic measures. Furthermore, initiatives by WHO to eradicate malaria by 2030 will further contribute towards the growth of this market. Developme

Malaria Vaccines Market Concentration By Players

To learn more about this report, Request sample copy

Key Developments:

  • In May 2024, United Nations International Children's Emergency FundUNICEF, delivered over 43,000 doses of the R21/Matrix-M Malaria Vaccine to Bangui, Central African Republic, with 120,000 additional doses arriving soon. This marks the first use of the R21 vaccine in routine childhood immunization. R21, the second malaria vaccine recommended by the World Health Organization (WHO), joins the RTS, S vaccine in scaling up malaria vaccination across Africa. Funded by Gavi, the Vaccine Alliance, this expanded supply is set to transform child health and survival in endemic areas.
  • In October 2023, UNICEF, the United Nations agency for children, announced a long-term agreement with Serum Life Sciences to secure the supply of the R21/Matrix-M Malaria Vaccine, conditional on World Health Organization (WHO) pre-qualification. Deliveries are expected to begin mid-2024, complementing the rollout of the first malaria vaccine, RTS, S, starting late 2023.
  • In September 2022, GSK plc, a biopharma company, announced that Mosquirix (RTS, S/AS01), its groundbreaking malaria vaccine, has received World Health Organization (WHO) prequalification, the first for a malaria vaccine. This milestone enables procurement by UN agencies like UNICEF in collaboration with Gavi, the Vaccine Alliance, for rollout in countries with moderate to high Plasmodium falciparum malaria transmission.

Top Strategies Followed by Global Malaria Vaccines Market Players

  • Leading companies prioritize substantial research and development to innovate high-performance malaria vaccines
    • For instance, the Serum Institute of India, in collaboration with the University of Oxford, developed the R21/Matrix-M malaria vaccine, which received prequalification status from the World Health Organization (WHO) in 2024, enabling mass distribution
  • Mid-level companies are focusing on delivering budget-friendly products
    • For example, Hilleman Laboratories, a joint venture between Merck & Co., Inc. and the Wellcome Trust, is dedicated to developing affordable vaccines for developing nations. They have undertaken projects such as creating a heat-stable rotavirus vaccine and an optimized cholera vaccine, aiming to reduce production costs and improve accessibility in low-resource settings.
  • Small players often target niche markets. For instance, in 2024, Ocean Biomedical, a biopharmaceutical company based in Providence, Rhode Island, U.S., announced the discovery of a malaria vaccine. This development underscores the company's commitment to addressing malaria through innovative solutions.

Emerging Startups - Malaria Vaccines Industry Ecosystem

  • Startups like BioNTech are developing advanced technologies, including mRNA-based vaccines for malaria. Their innovative approach could significantly impact market dynamics by providing faster and more effective vaccine solutions.
  • Startups are increasingly focusing on sustainability. For example, a startup named EcoVax is working on eco-friendly vaccine production methods, utilizing recycled materials to reduce environmental impact.
  • Emerging startups are addressing unique market needs. For instance, a startup called MalariaTech is developing a vaccine specifically for Plasmodium vivax, filling a critical gap in the market. MalariaTech is concentrating on a vaccine specifically for Plasmodium vivax, the most widespread form of malaria. This vaccine aims to fill a significant gap in the market, as current vaccines and treatments are primarily effective against falciparum. P. vivax presents unique challenges in terms of its ability to relapse and its complex life cycle, making the development of a targeted vaccine crucial.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2025 Coherent Market Insights Pvt Ltd. All Rights Reserved.